## AGENDA ITEM

**Wednesday February 27**

<table>
<thead>
<tr>
<th>Time</th>
<th>Agenda Item</th>
<th>Purpose</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Welcome &amp; Introductions</td>
<td></td>
<td>Dr. Dale Morse (Chair, ACIP) Dr. Larry Pickering (Executive Secretary, ACIP; CDC)</td>
</tr>
<tr>
<td>8:30</td>
<td>Influenza Vaccines</td>
<td>Information</td>
<td>Dr. Anthony Fiore (CDC/NCIRD/ID) Dr. Alexander Klimov (CDC/NCIRD/ID) Dr. David Shay (CDC/NCIRD/ID)</td>
</tr>
<tr>
<td></td>
<td>• Surveillance update</td>
<td>Discussion</td>
<td>Dr. Anthony Fiore (CDC/NCIRD/ID) Dr. Kathleen Neuzil (ACIP, WG Chair) Dr. Gregory Wallace (CDC/NCIRD/ID)</td>
</tr>
<tr>
<td></td>
<td>• Vaccine strain selection and antiviral resistance</td>
<td>Discussion</td>
<td>Dr. Anthony Fiore (CDC/NCIRD/ID) Dr. Kathleen Neuzil (ACIP, WG Chair) Dr. Gregory Wallace (CDC/NCIRD/ID)</td>
</tr>
<tr>
<td></td>
<td>• Vaccine effectiveness among 6-23 month old children</td>
<td>Discussion</td>
<td>Dr. Anthony Fiore (CDC/NCIRD/ID) Dr. Kathleen Neuzil (ACIP, WG Chair) Dr. Gregory Wallace (CDC/NCIRD/ID)</td>
</tr>
<tr>
<td></td>
<td>• 2008 vaccination recommendations</td>
<td>Vote</td>
<td>Dr. Amanda Cohn (CDC/NCIRD/DBD)</td>
</tr>
<tr>
<td>10:00</td>
<td><strong>Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Meningococcal Conjugate Vaccine (MCV4)</td>
<td>Information</td>
<td>Dr. Carol Baker (ACIP, WG Chair) Dr. Amanda Cohn (CDC/NCIRD/DBD) Dr. Ismael Ortega-Sanchez (CDC/NCIRD/DVD)</td>
</tr>
<tr>
<td></td>
<td>• Overview of session and Working Group update</td>
<td>Discussion</td>
<td>Dr. Carol Baker (ACIP, WG Chair) Dr. Amanda Cohn (CDC/NCIRD/DBD) Dr. Ismael Ortega-Sanchez (CDC/NCIRD/DVD)</td>
</tr>
<tr>
<td></td>
<td>• Burden of meningococcal disease among infants and children</td>
<td>Vote</td>
<td>Dr. Amanda Cohn (CDC/NCIRD/DBD)</td>
</tr>
<tr>
<td></td>
<td>• Recommendations for use of MCV4 among 2-10 year old children</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td><strong>Lunch</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td>Use of Vaccines during Pregnancy &amp; Breastfeeding</td>
<td>Information</td>
<td>Dr. Carol Baker (ACIP, WG Chair) Dr. Stephanie Schrag (CDC/NCIRD/DBD) Dr. Carol Baker (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>• Update on the activities of the ACIP Working Group on Vaccination</td>
<td>Discussion</td>
<td>Dr. Carol Baker (ACIP, WG Chair) Dr. Stephanie Schrag (CDC/NCIRD/DBD) Dr. Carol Baker (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>during Pregnancy and Breastfeeding</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Draft guiding principles for standardization of ACIP recommendations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>regarding vaccination during pregnancy and breastfeeding</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Overview of session and Working Group update</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td>Human Papillomavirus (HPV) Vaccines</td>
<td>Information</td>
<td>Dr. Janet Englund (ACIP, WG Chair) Dr. Gary Dubin (GSK) Dr. Richard Haupt (Merck)</td>
</tr>
<tr>
<td></td>
<td>• Overview of session and Working Group update</td>
<td>Information</td>
<td>Dr. Janet Englund (ACIP, WG Chair) Dr. Gary Dubin (GSK) Dr. Richard Haupt (Merck)</td>
</tr>
<tr>
<td></td>
<td>• Update on bivalent HPV vaccine</td>
<td>Information</td>
<td>Dr. Janet Englund (ACIP, WG Chair) Dr. Gary Dubin (GSK) Dr. Richard Haupt (Merck)</td>
</tr>
<tr>
<td></td>
<td>• Quadrivalent HPV vaccine: end-of-study results and adult women</td>
<td>Information</td>
<td>Dr. Eileen Dunne (CDC/NCHHSTP/DSTDP)</td>
</tr>
<tr>
<td></td>
<td>• Epidemiology of HPV infection in older women</td>
<td>Information</td>
<td>Dr. Eileen Dunne (CDC/NCHHSTP/DSTDP)</td>
</tr>
<tr>
<td></td>
<td>• Cost effectiveness studies</td>
<td>Information</td>
<td>Dr. Eileen Dunne (CDC/NCHHSTP/DSTDP)</td>
</tr>
<tr>
<td></td>
<td>• Considerations for vaccination recommendations</td>
<td>Discussion</td>
<td>Dr. Lauri Markowitz (CDC/NCHHSTP/DSTDP)</td>
</tr>
<tr>
<td></td>
<td>among women &gt;26 years of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00</td>
<td><strong>Break</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
February 27 - continued

3:30 **Vaccine Safety Updates**
- Introduction
- Overview of VSD rapid cycle analysis (RCA)
- RCA results for Measles Mumps Rubella Varicella (MMRV) Vaccine (ProQuad®)
- Phase IV results for MMRV Vaccine
- Summary and vote

4:45 **Vaccine Supply**

5:15 Public Comment

5:30 Adjourn

Thursday February 28

8:00 **Unfinished Business**

8:20 **Measles Outbreak - San Diego, CA, Jan-Feb 2008**

8:30 **Agency Updates (CDC/CCID/NCIRD, CMS, DOD, DVA, FDA, HRSA, IHS, NIH, NVPO)**

8:45 **Rotavirus Vaccines**
- Update from Rotavirus Vaccines Working Group
- Working Group considerations and draft of proposed recommendations
- Adoption of rotavirus vaccine by pediatric and family medicine physicians

9:45 **Update: Implementation of Approach to Economic Analyses**

9:50 **Rabies Vaccines and Biologicals**
- Update on supply of rabies vaccines and biologicals

10:10 **Update: General Recommendations**

10:30 **Break**

10:45 **Japanese Encephalitis Vaccines**
- Update from Japanese Encephalitis (JE) Vaccines Working Group
- JE vaccine for U.S. travelers
- JE vaccine availability in the U.S.
- A new inactivated cell culture-derived JE vaccine for adult travelers
- Questions and discussion
February 28 - continued

11:45 Anthrax Vaccines
- Introduction
- Background information on anthrax vaccine
- Anthrax Vaccine Adsorbed: Overview of Safety Studies
- Presentation of data on anthrax vaccine from the Anthrax Vaccine Research Program’s ongoing clinical trial

Information
- Dr. Dale Morse (ACIP, WG Chair)
- Dr. Jennifer Wright (CDC/NCIRD/DBD)

Information
- COL. Ted Cieslak (Department of Defense)

Information
- Dr. Jennifer Wright and Dr. Conrad Quinn (CDC/NCIRD/DBD)

Discussion
- Dr. Dale Morse (ACIP, WG Chair)
- Dr. Jennifer Wright (CDC/NCIRD/DBD)

1:10 Public Comment

1:30 Adjourn

Acronyms
ACIP Advisory Committee on Immunization Practices
CCID Coordinating Center for Infectious Diseases
CDC Centers for Disease Control & Prevention
CMS Centers for Medicare and Medicaid Services
DBD Division of Bacterial Diseases [of NCIRD]
DOD Department of Defense
DSTDP Division of Sexually Transmitted Diseases Prevention [of NCHSTP]
DVA Department of Veterans Affairs
DVBID Division of Vector-Borne Infectious Diseases
DVD Division of Viral Diseases [of NCIRD]
DVI Division of Viral Hepatitis [of NCHSTP]
DVRD Division of Viral and Rickettsial Diseases
FDA Food and Drug Administration
HRSA Health Resources and Services Administration
ID Influenza Division [of NCIRD]
IHS Indian Health Service
ISD Immunization Services Division [of NCIRD]
ISO Immunization Safety Office (of CDC/OD/Office of the Chief Science Officer)
NCHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/CCID]
NCIRD CDC National Center for Immunization & Respiratory Diseases [of CDC/CCID]
NCPDCID National Center for Preparedness, Detection, and Control of Infectious Diseases
NCZVED National Center for Zoonotic, Vector-Borne, and Enteric Diseases [of CDC/CCID]
NIH National Institutes of Health
NVAC National Vaccine Advisory Committee
NVPO National Vaccine Program Office
OD Office of the Director [of CDC]
TBD to be determined
VSD Vaccine Safety Datalink
WG Working Group

http://www.cdc.gov/vaccines/recs/acip/downloads/agenda-feb08.pdf